High-risk Medulloblastoma-Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity

Allison M Martin¹, Sadhana Jackson^{2

3}

Affiliations

¹ Department of Pediatrics, Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
² Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
³ Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Comment

Allison M Martin et al. JAMA Oncol. 2021.

. 2021 Sep 1;7(9):1322-1323.

doi: 10.1001/jamaoncol.2021.2084.

Allison M Martin¹, Sadhana Jackson^{2

3}

¹ Department of Pediatrics, Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
² Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
³ Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

No abstract available

Comment on

Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
Leary SES, Packer RJ, Li Y, Billups CA, Smith KS, Jaju A, Heier L, Burger P, Walsh K, Han Y, Embry L, Hadley J, Kumar R, Michalski J, Hwang E, Gajjar A, Pollack IF, Fouladi M, Northcott PA, Olson JM. Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321. doi: 10.1001/jamaoncol.2021.2224. JAMA Oncol. 2021. PMID: 34292305 Free PMC article. Clinical Trial.